Chronic Obstructive Pulmonary Disease (COPD) Market Growth, Size, Trends Analysis- By Type, By Treatment Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Chronic Obstructive Pulmonary Disease (COPD) Market Growth, Size, Trends Analysis- By Type, By Treatment Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Chronic Obstructive Pulmonary Disease (COPD) Market Introduction and Overview

According to SPER Market Research, ‘Global Chronic Obstructive Pulmonary Disease (COPD) Market Size- By Type, By Treatment Type, By End User – Regional Outlook, Competitive Strategies and Segment Forecast to 2033’ states that the Global Chronic Obstructive Pulmonary Disease (COPD) Market is estimated to reach USD 33.31 billion by 2033 with a CAGR of 4.68%.

Chronic obstructive pulmonary disease (COPD), a degenerative lung disease, is characterized by persistent respiratory symptoms and airflow restriction. It encompasses conditions like emphysema and chronic bronchitis that are primarily caused by long-term exposure to harmful gases or particles, most commonly by smoking. Coughing, wheezing, and increased mucus production are all symptoms of the illness’s inflammation and destruction to the lung tissue and airways, which makes breathing difficult.

The global market for chronic obstructive pulmonary disease (COPD) has been significantly impacted by the COVID-19 pandemic, presenting both potential and challenges. Because of their underlying respiratory disorders, those with COPD were more vulnerable during the pandemic, leading to an increase in hospitalizations and a focus on respiratory health. Prioritizing COVID-19 responses often caused healthcare systems to disrupt regular care and management of COPD, which impacted patients’ access to medications and made their illnesses worse.

Scope of the report:

Report Metric Details
Market size available for years 2020-2033
Base year considered 2023
Forecast period 2024-2033
Segments covered By Type, By Treatment Type, By End User
Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
Companies Covered Pfizer Inc, Merck & Co., Inc, Novartis AG, AstraZeneca, GlaxoSmithKline plc, Roche (F. Hoffmann-La Roche Ltd, Switzerland), Abbott, Boehringer Ingelheim International GmbH, Biogen, Teva Pharmaceutical Industries Ltd, Others.

Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation:

By Type: Based on the Type, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Chronic Bronchitis, Emphysema.

By Treatment Type: Based on the Treatment Type, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Bronchodilator monotherapy, short-acting beta2-agonists (SABAs), long-acting beta2-agonists (LABAs), anti-cholinergic agents, anti-inflammatory drugs, oral and inhaled corticosteroids, anti-leukotrienes, surgery, lung volume reduction surgery (LVRS), lung transplant, bullectomy and others.

By End User: Based on the End User, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Hospitals, Homecare Settings, Clinics, Others

By Region: This research also include data for North America, Europe, Asia-Pacific Middle East & Africa and South America.